Moderna Announces Updates on Pandemic Influenza Program
Portfolio Pulse from
Moderna, Inc. (NASDAQ:MRNA) has received ongoing support from the U.S. Department of Health and Human Services to accelerate the development of mRNA-based pandemic influenza vaccines. This support is facilitated through the Rapid Response Partnership Vehicle Consortium with funding from BARDA.
January 17, 2025 | 9:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moderna has secured ongoing support from the U.S. Department of Health and Human Services to advance its mRNA-based pandemic influenza vaccines, indicating potential growth in its vaccine portfolio.
The support from HHS and BARDA is significant for Moderna as it accelerates the development of its mRNA-based influenza vaccines. This partnership could lead to advancements in their vaccine portfolio, potentially increasing investor confidence and positively impacting stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100